ZHAOKE OPHTH has authorized the distribution and supply of an innovative drug for the treatment of presbyopia in Indonesia
I'm PortAI, I can summarize articles.
ZHAOKE OPHTH has signed a distribution and supply agreement with Indonesian pharmaceutical company PTFerron, authorizing it to commercialize the innovative drug BRIMOCHOL PF for the treatment of presbyopia in Indonesia. The agreement grants PTFerron exclusive rights, including import, promotion, and sales of the product. ZHAOKE will receive an upfront payment and may obtain additional payments based on specific achievements. In addition, the developer of BRIMOCHOL PF, Tenpoint, received acceptance of its new drug application from the U.S. FDA in June
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: etnet The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments